Backing the Future of Drug Development
Revalia Bio is building the infrastructure layer for human-relevant drug and device testing — replacing animal models with organ-level human data.
The Opportunity
$2B+ per drug
The average cost to bring a single drug to market, with 90% of clinical trials failing. The industry needs a fundamentally new approach.
Platform moat
Five integrated pillars — organ access network, proprietary hardware, human data stack, software suite (Rio), and biomedical innovation network — create compounding defensibility.
Revenue from day one
Revalia has been revenue-generating since founding in 2023, with contracts from two of the world's top 10 pharmaceutical companies.
Government validation
Awarded up to $26.7M by ARPA-H — the U.S. government's most selective health research funding body — to advance the Human Data Trials platform.
Traction
Founded by Yale scientists Greg Tietjen & Jenna DiRito
Revenue-generating from day one with pharma partnerships
Raised $14.5M Series A led by America's Frontier Fund
Awarded up to $26.7M ARPA-H contract
Expanded to 8,000 sq ft facility in New Haven, CT
CEO Greg Tietjen named TED Fellow 2026
Platform Moat
Organ Access Network
Nationwide delivery of viable human organs from trusted sources. Rapid access to diverse patient profiles. The foundation of every Human Data Trial.
Hardware
Proprietary organ perfusion technology. 8,000 sq ft facility in New Haven, CT. 24/7 support from transplant surgeons. Organs kept viable for research using cutting-edge perfusion systems.
Integrated Human Data Stack
Four layers of human biological data — patient history, organ function, tissue biopsies, and organoid data — integrated and accessible through our software.
Software Suite (Rio)
Rio Assist for data input and management. Rio Insight for designing and running Human Data Trials. Purpose-built for translational research.
Biomedical Innovation Network
Expert guidance on trial design, regulatory support, and industry collaboration. Connecting pharma, biotech, and researchers with the right expertise.
Leadership
Greg Tietjen, PhD
Co-Founder & CEO
Former Yale assistant professor
Jenna DiRito, PhD
Co-Founder & COO
Human organ research operations
Janeta Nikolovski, PhD
Chief Data & Innovation Officer
Former J&J executive
Board of Directors
Brian Wilcove
Managing Partner, America's Frontier Fund
Ben Yu
Investor & Entrepreneur
Roger Ferguson
Board Member
Milad Alucozai, PhD
Co-Founder & GP, Pamir Ventures
Backed By
America's Frontier Fund
Lead Investor
Sierra Ventures
Investor
National Kidney Foundation
Strategic Partner
CT Innovations
Investor
Bridge the gap between biology and breakthrough
Request our investor deck and financial overview.